Home >> Top News >> Illumina to buy PacBio for $1.2 billion

Illumina to buy PacBio for $1.2 billion

Print Friendly, PDF & Email

Nov. 7, 2018Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina’s short-read sequencing platforms with PacBio’s long-read sequencing capabilities to help researchers advance their discoveries faster and clinicians offer new tests economically.

“PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing. Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception,” Francis deSouza, president and CEO of Illumina, said in a press release. “PacBio’s relentless pursuit to improve sequencing accuracy, while driving down the cost, underscores the potential of long-reads to expand sequencing to new customers and applications.”

Illumina expects to close the transaction in mid-2019.


Check Also

IIlumina’s iSeq 100, Thermo Fisher agreement

Jan. 11, 2018—Illumina announced Tuesday the launch of its iSeq 100 Sequencing System, a next-generation...